Schedule-dependent cytotoxicity of sunitinib and TRAIL in human non-small cell lung cancer cells with or without EGFR and KRAS mutations

YX Bao, XD Zhao, HB Deng, CL Lu, Y Guo, X Lu… - Cellular Oncology, 2016 - Springer
Background Non-small cell lung cancer (NSCLC) patients who do initially respond to
epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) may eventually …
被引用次数：10 相关文章

Schedule-dependent cytotoxicity of sunitinib and TRAIL in human non-small cell lung cancer cells with or without EGFR and KRAS mutations

YX Bao, XD Zhao, HB Deng, CL Lu… - Cellular oncology …, 2016 - pubmed.ncbi.nlm.nih.gov
Background Non-small cell lung cancer (NSCLC) patients who do initially respond to
epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) may eventually …

Schedule-dependent cytotoxicity of sunitinib and TRAIL in human non-small cell lung cancer cells with or without EGFR and KRAS mutations

YX Bao, XD Zhao, HB Deng, CL Lu, Y Guo, X Lu… - Cellular Oncology, 2016 - infona.pl
Background Non-small cell lung cancer (NSCLC) patients who do initially respond to
epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) may eventually …

Schedule-dependent cytotoxicity of sunitinib and TRAIL in human non-small cell lung cancer cells with or without EGFR and KRAS mutations.

YX Bao, XD Zhao, HB Deng, CL Lu, Y Guo… - Cellular Oncology …, 2016 - europepmc.org
Background Non-small cell lung cancer (NSCLC) patients who do initially respond to
epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) may eventually …

Schedule-dependent cytotoxicity of sunitinib and TRAIL in human non-small cell lung cancer cells with or without EGFR and KRAS mutations.

YX Bao, XD Zhao, HB Deng, CL Lu… - Cellular Oncology …, 2016 - search.ebscohost.com
Background: Non-small cell lung cancer (NSCLC) patients who do initially respond to
epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) may eventually …

Schedule-dependent cytotoxicity of sunitinib and TRAIL in human non-small cell lung cancer cells with or without EGFR and KRAS mutations.

YX Bao, XD Zhao, HB Deng, CL Lu… - Cellular Oncology …, 2016 - search.ebscohost.com
Background: Non-small cell lung cancer (NSCLC) patients who do initially respond to
epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) may eventually …

[引用][C] Schedule-dependent cytotoxicity of sunitinib and TRAIL in human non-small cell lung cancer cells with or without EGFR and KRAS mutations

YX Bao, XD Zhao, HB Deng, CL Lu, Y Guo, X Lu… - Cellular …, 2016 - IOS Press